New York, Jan 9, 2026, 14:40 (EST) — Regular session
- J&J shares slip after the company laid out a Trump administration drug-pricing agreement linked to tariff exemptions
- Investors weigh whether price concessions are worth it as trade risks ease for the sector
- Next up: J&J’s appearance at JPMorgan’s conference on Jan. 12, followed by quarterly results on Jan. 21
Johnson & Johnson shares slipped about 0.5% to $204.76 on Friday after the company said it struck an agreement with President Donald Trump’s administration to lower drug prices for Americans in return for exemptions from U.S. tariffs. Johnson & Johnson did not say which medicines are included or how large the price cuts would be.
The update is in focus as drugmakers face pressure to shrink the gap between U.S. prices and those in other wealthy countries, and Washington has dangled tariff relief — import duties that can raise costs and disrupt supply chains. “Worst-case pricing fears are clearly not coming to pass,” Linden Thomson, a senior portfolio manager at Candriam Asset Management, said this week about the earlier round of industry agreements. Reuters
Johnson & Johnson said it will join TrumpRx.gov, a direct-to-patient platform, and committed to two new manufacturing facilities in North Carolina and Pennsylvania under its previously announced $55 billion U.S. investment plan. Chief Executive Joaquin Duato said the agreement can “deliver real results for patients.” JNJ.com
The stock slipped with healthcare trailing the broader tape. The Health Care Select Sector SPDR Fund was down about 0.2% as the SPDR S&P 500 ETF Trust climbed about 0.8%; Pfizer and Merck edged up, while Eli Lilly dropped.
Johnson & Johnson finished Thursday at $205.75. Over the past 52 weeks, it has traded in a range of $140.68 to $215.19, according to the company’s investor data.
Investors may get more color from management at the J.P. Morgan Healthcare Conference in San Francisco, where Johnson & Johnson is slated for a fireside chat on Jan. 12 at 11:15 a.m. ET. The conference runs Jan. 12-15.
But it’s not a clean trade-off. With no detail on which drugs are covered or how the discounts would work, traders are stuck guessing how fast pricing pressure could hit margins — and whether those kinds of terms bleed beyond a narrow set of products.
The next hard catalyst lands on Jan. 21, when Johnson & Johnson reports fourth-quarter results and hosts its earnings call at 8:30 a.m. ET — a checkpoint for any read-through to 2026 guidance.
